Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
Japan’s ruling Liberal Democratic Party (LDP) on January 21 announced its first slate of endorsed candidates for the upcoming Lower House election, naming 284 contenders — 272 in single-seat districts and 12 in the proportional representation segment. The roster includes…
To read the full story
Related Article
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
- LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
- Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
REGULATORY
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
- Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
January 22, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
- MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…